JW-65

• Description :

  JW-65 (compound 20) is a TRPC3 inhibitor. JW-65 can be used in neurological and cardiovascular disease related research[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  TRP Channel

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/jw-65.html

• Purity :

  99.05

• Solubility :

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  FC(C1=C(C(NCC)=O)C=NN1C2=CC=C(C=C2)N(C=CC(Cl)=C3Cl)C3=O)(F)F

• Molecular Formula :

  C18H13Cl2F3N4O2

• Molecular Weight :

  445.22

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Zhang S, et al. Discovery of a Highly Selective and Potent TRPC3 Inhibitor with High Metabolic Stability and Low Toxicity. ACS Med Chem Lett. 2021 Mar 5;12 (4) :572-578.|[2]Nagib MM, et al. Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects. Epilepsia. 2022 Apr;63 (4) :1003-1015. |[3]Silva-Cardoso GK, et al. Inhibition of TRPC3 channels suppresses seizure susceptibility in the genetically-epilepsy prone rats. Eur J Pharmacol. 2024 Aug 15;977:176722.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  TRPC3

• CAS Number :

  [2763378-71-6]